Date:8/14/2009

7,197 212,055 184,932 548,239 Interest expense (5,266) (205,286) (170,924) (442,128) Other income (expense), net 63,823 (22,242) 263,496 (70,957) Interest expense related to bridge loan warrants - - - - --- --- --- --- Net loss (7,113,114) (4,507,978) (15,650,877) (9,580,314) Deemed dividend - Series C convertible preferred stockholders - - - - --- --- --- --- Loss attributable to common stockholders $(7,113,114) $(4,507,978) $(15,650,877) $(9,580,314) =========== =========== ============ =========== Basic and diluted net loss per share $(0.54) $(12.09) $(1.42) $(26.16) ====== ======= ====== ======= Weighted average common shares outstanding 13,070,211 372,849 11,047,881 366,226 ========== ======= ========== ======= Period From Inception (January 8, 2002) to June 30, 2009 ---------------- Operating expenses: Research and development $47,798,800 General and administrative 30,225,845 Merger related transaction costs 4,190,623 --------- Total operating expenses 82,215,268 -------
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine news :

1. Transcept Pharmaceuticals to Report Second Quarter 2009 Results
2. Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
3. Transcept Pharmaceuticals to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
4. Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo(R)
5. Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009
6. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
7. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
8. Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel
9. Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
10. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
11. Transcept Pharmaceuticals to Present at Two Upcoming Conferences